Wat is de prijs voor TMS Co., Ltd. (4891)

Het prijs van TMS Co., Ltd. (4891) is $0.73072946

Wat is de marktkapitalisatie voor TMS Co., Ltd. (4891)

Marktkapitalisatie voorTMS Co., Ltd. (4891) is $33.30M

TMS Co., Ltd. (4891) Omzet

Established in 2005 and headquartered in Fuchu, Japan, TMS Co., Ltd. focuses on the research, development, manufacturing, and commercialization of pharmaceuticals, quasi-drugs, drug substances, medical devices, and various medical commodities. The company's pipeline includes TMS-007, an SMTP congener demonstrating both prothrombolytic and anti-inflammatory/antioxidative activities, which has advanced through Phase 2a clinical trials for the treatment of acute ischemic stroke. Additionally, TMS-008, another SMTP congener with anti-inflammatory/antioxidative properties, is undergoing nonclinical development for addressing inflammatory complications like acute kidney injury and cancer cachexia. A third product candidate, TMS-009, is currently in preclinical development. TMS Co., Ltd. collaborates with Hokkaido University and Kanazawa University to assess the potential of its drug candidates, has a joint research agreement with Teikyo University to identify renal function biomarkers, and maintains a strategic alliance with Ji Xing Pharmaceuticals Limited.

Jaar	Omzet	Wijzigen
Niet genoeg gegevens voor de verstrekte datums.

Jaar

Omzet

Wijzigen

Niet genoeg gegevens voor de verstrekte datums.

Bedrijf	Omzet	Omzetverschil	Land
Vertex Pharmaceuticals Incorporated VRTX.US	$12.62B	-	US
Moderna, Inc. MRNA.US	$2.23B	-	US
Argenx SE ARGX.US	$6.02B	-	NL
CSL Limited CSL.AX	$15.70B	-	AU
Lonza Group AG LONN.SW	-	-	CH

Bedrijf

Omzet

Omzetverschil

Land

Vertex Pharmaceuticals Incorporated

VRTX.US

$12.62B

Moderna, Inc.

MRNA.US

$2.23B

Argenx SE

ARGX.US

$6.02B

CSL Limited

CSL.AX

$15.70B

Lonza Group AG

LONN.SW

TMS Co., Ltd.

4891

Categorie